DANBIO: A nationwide registry of biological therapies in Denmark

Clinical and Experimental Rheumatology

Volumn 23, Issue 5 SUPPL. 39, 2005, Pages

  Hetland, Merete L ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Adalimumab; Ankylosing spondylitis; Database; Drug surveillance; Etanercept; Infliximab; Observational studies; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; GLUCOCORTICOID; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTICLE; BIOLOGICAL THERAPY; DENMARK; DRUG HYPERSENSITIVITY; ECZEMA; HUMAN; INCIDENCE; INFECTION; LUPUS LIKE SYNDROME; PREVALENCE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REGISTER; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; UNSPECIFIED SIDE EFFECT; FACTUAL DATABASE; FEMALE; HOSPITALIZATION; LONGITUDINAL STUDY; MALE; METHODOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RHEUMATOLOGY; ADULT; ADVERSE DRUG REACTION; DATA BASE; DEMOGRAPHY; DISEASE ACTIVITY; DRUG WITHDRAWAL; LATENT TUBERCULOSIS; LUPUS VULGARIS; MAJOR CLINICAL STUDY; ONLINE SYSTEM; RHEUMATOLOGIST;

ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; DATABASES, FACTUAL; DENMARK; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; PROGNOSIS; REGISTRIES; RHEUMATIC DISEASES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 33644797791     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. SOKKA T, KRISHNAN E, HAKKINEN A, HANNONEN P: Functional disability in rheumatoid arthritis patients compared with a community population in Finland. Arthritis Rheum 2003; 48: 59-63.
2. GEBOREK P, CRNKIC M, PETERSSON IF, SAXNE T: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
3. KVIEN TK, UHLIG T: The Oslo experience with arthritis registries; Clin Exp Rheumatol 2003; 21 (Suppl. 31): S118-S122.
4. VAN VOLLENHOVEN RF, ERNESTAM S, HARJU A, BRATT J, KLARESKOG L: Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003; 5: R347-R351.
5. PHILLIPS K, HUSNI ME, KARLSON EW, COBLYN JS: Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002; 47: 17-21.
6. HETLAND ML, UNKERSKOV J, RAVN T et al.: Routine database registration of biological therapy increases the reporting of adverse events twenty-fold in clinical practise. First results from the Danish database (DANBIO). Scand J Rheumatol 2005; 34: 40-44.
7. www.das-score.nl. internet (2004).
8. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
9. DANBIO-online. www.danbio-online.dk. 1-8-2005.
10. HJARDEM E, HETLAND ML, OSTERGAARD M, KROGH NS, KVIEN TK: Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent. Ann Rheum Dis 2005; 64: 1220-3.
11. HJARDEM E, ØSTERGAARD M, HETLAND ML: Do patients benefit from switching to a second biologic drug when the first is withdrawn due to lack of efficacy or adverse events? Arthritis Rheum 2004; 50: S392-S393.
12. ØSTERGAARD M, UNKERSKOV J, FRIIS M et al.: Infliximab and etanercept reduce rheumatoid disease activity significantly, but clinical remission is only present in 20% of visits - results from the Danish Database for Biological Therapies in Rheumatology. Ann Rheum Dis 2003; 62: 160.
13. LINDE L, HETLAND ML, KROGH NS et al.: Efficacy, safety and drug survival of TNF-alpha inhibitors in ankylosing spondylitis and psoriatic arthritis: data from the nationwide Danish "DANBIO" database. Arthritis Rheum 2005 (abstract).